With the publication of the final Cass Report and new NHSE commissioning policies, the APC has agreed an AMBER status for gender affirming hormones in children and young people.  This applies to recommendations from both NHS and private providers subject to appropriate shared care protocols being in place.

The following guidance has also been updated:

• Primary care prescribing guidance, for people who access Gender Identity Services.
• NHSE guidance on prescribing and dispensing restrictions for puberty blockers and gender affirming hormones

In December 2023, a guide to support primary care prescribing for people who access gender identity services was agreed by the APC. 

The guide includes information on children and young people, requests to prescribe, shared care, on-going care and private providers.